Cryo Cell International Inc: Form 10-K for the period ended Nov 30, 2016
Filed with the SEC on Feb 28, 2017 and accepted by EDGAR at Feb 28, 2017, 22:27 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-11-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2015-12-01 to 2016-11-30 | $23.1m | us-gaap:Revenues |
| Cost of revenue | 12 months2015-12-01 to 2016-11-30 | $5.8m | us-gaap:CostOfServices |
| Research and development | 12 months2015-12-01 to 2016-11-30 | $53.1k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2015-12-01 to 2016-11-30 | $14.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2015-12-01 to 2016-11-30 | $433.6k | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2015-12-01 to 2016-11-30 | $947.3k | us-gaap:InterestExpense |
| Income tax | 12 months2015-12-01 to 2016-11-30 | −$1.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2015-12-01 to 2016-11-30 | −$1.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2015-12-01 to 2016-11-30 | −$0.16 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2015-12-01 to 2016-11-30 | −$0.16 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2015-12-01 to 2016-11-30 | 8,112,791 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2015-12-01 to 2016-11-30 | $5.0m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 12 months2015-12-01 to 2016-11-30 | $343.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2015-12-01 to 2016-11-30 | $10.8m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2016-11-30 | $3.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2016-11-30 | $9.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2016-11-30 | $19.5m | us-gaap:Assets |
| Current liabilities | At period end2016-11-30 | $13.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2016-11-30 | $35.0m | us-gaap:Liabilities |
| Long-term debt | At period end2016-11-30 | $1.4m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2016-11-30 | −$15.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001193125-17-062739. Last ingested by Listed: Oct 24, 2026, 14:58 ET. Listed shows no prices and gives no investment advice.